A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Clinical trial NCT05968326 · RECRUITING
Trial details
- NCT number
- NCT05968326
- Sponsor
- Genentech, Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-18
- Primary completion
- 2031-01-01
- Enrollment
- 260
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.